<code id='0381AF366F'></code><style id='0381AF366F'></style>
    • <acronym id='0381AF366F'></acronym>
      <center id='0381AF366F'><center id='0381AF366F'><tfoot id='0381AF366F'></tfoot></center><abbr id='0381AF366F'><dir id='0381AF366F'><tfoot id='0381AF366F'></tfoot><noframes id='0381AF366F'>

    • <optgroup id='0381AF366F'><strike id='0381AF366F'><sup id='0381AF366F'></sup></strike><code id='0381AF366F'></code></optgroup>
        1. <b id='0381AF366F'><label id='0381AF366F'><select id='0381AF366F'><dt id='0381AF366F'><span id='0381AF366F'></span></dt></select></label></b><u id='0381AF366F'></u>
          <i id='0381AF366F'><strike id='0381AF366F'><tt id='0381AF366F'><pre id='0381AF366F'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:35
          Darron Cummings/AP

          In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

          The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

          advertisement

          A date for the meeting has not been set yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Patients, digital health players weigh in on FTC's data privacy plan
          Patients, digital health players weigh in on FTC's data privacy plan

          AdobeThisyearhasseentheFederalTradeCommissioncrackdownondigitalhealthcompanies’irresponsibledatause.

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more

          Schizophrenia gene found to be linked to cells' energy dysfunction

          Toscientists'surpriseinanewstudy,acommongeneticdeletioninschizophreniacaseswaslinkedtoproblemsinmito